According to these doctors' clinical trail data, Ponatinib is well tolerated and Adverse Events are manageable.
There is an exception, the French presentation. But the authors of that presentation admit that the number of their sample patients is small (only 19 patients). In principle of statistics, a small amount of data is not enough to make a meaningful conclusion. ********** The FDA: "24% patients (median treatment duration 1.3 years) have experienced serious adverse vascular events.
2-Year Follow-Up Of The PACE Trial by clinical trial doctors (to be presented on 12/09/2013): "Serious cardiovascular, cerebrovascular, and peripheral vascular AEs occurred in 6%, 3%, and 2% of pts (drug-related: 2%, 1%, 1%)."
Who is right? Whom to believe? I incline to believe the doctors who did the actual clinical trials and treated the patients in person.
Should not the FDA and Ariad explain the unbelievable discrepancy to the public scientifically, mathematically and statistically? ********** I strongly doubt the FDA is involved in any conspiracy. But where does the unbelievable discrepancy come from. Is it the clinical trial doctors' conspiracy?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.